{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T05:06:23Z","timestamp":1763183183602},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T00:00:00Z","timestamp":1550448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00108-019-0564-0","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T17:28:41Z","timestamp":1550510921000},"page":"411-419","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Moderne HIV-Therapie"],"prefix":"10.1007","volume":"60","author":[{"given":"C.","family":"Lehmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Malin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"F\u00e4tkenheuer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,18]]},"reference":[{"key":"564_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32462-0","author":"P Cahn","year":"2018","unstructured":"Cahn P, Madero JS, Arribas JR et al (2018) Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(18)32462-0","journal-title":"Lancet"},{"key":"564_CR2","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/00002030-200402200-00036","volume":"18","author":"C Cordes","year":"2004","unstructured":"Cordes C, Moll A, Kuecherer C et al (2004) HIV transmission despite HIV post-exposure prophylaxis after non-occupational exposure. AIDS 18:582\u2013584","journal-title":"AIDS"},{"key":"564_CR3","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","volume":"5","author":"ES Daar","year":"2018","unstructured":"Daar ES, Dejesus E, Ruane P et al (2018) Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a\u00a0randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV 5:e347\u2013e356","journal-title":"Lancet HIV"},{"key":"564_CR4","volume-title":"DHHS guidelines for the use of antiretroviral agents in adults and adolescents living with HIV","author":"Department of Health and Human Services","year":"2017","unstructured":"Department of Health and Human Services (2017) DHHS guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. \n                    https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf"},{"key":"564_CR5","volume-title":"Deutsch-\u00d6sterreichische Leitlinien zur antiretroviralen Therapie der HIV-1-Infektion (S2k). AWMF-Register-Nr.: 055-001","author":"Deutsche AIDS Gesellschaft","year":"2017","unstructured":"Deutsche AIDS Gesellschaft (2017) Deutsch-\u00d6sterreichische Leitlinien zur antiretroviralen Therapie der HIV-1-Infektion (S2k). AWMF-Register-Nr.: 055-001. \n                    https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/055-001l_Antiretrovirale_Therapie_der_HIV_Infektion__2014-05.pdf"},{"key":"564_CR6","volume-title":"Deutsch-\u00d6sterreichische Leitlinien zur Prophylaxe der HIV-Infektion (update 2018). AWMF-Register-Nr.: 055-004","author":"Deutsche AIDS Gesellschaft","year":"2018","unstructured":"Deutsche AIDS Gesellschaft (2018) Deutsch-\u00d6sterreichische Leitlinien zur Prophylaxe der HIV-Infektion (update 2018). AWMF-Register-Nr.: 055-004. \n                    https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/055-004l_S2k_Medikamentoese-Postexpositionsprophylaxe-PEP-nach-HIV-Exposition_2018-12.pdf"},{"key":"564_CR7","volume-title":"HIV-Pr\u00e4expositionsprophylaxe (S2k). AWMF-Register-Nr.: 055-008","author":"Deutsche AIDS Gesellschaft","year":"2018","unstructured":"Deutsche AIDS Gesellschaft (2018) HIV-Pr\u00e4expositionsprophylaxe (S2k). AWMF-Register-Nr.: 055-008. \n                    https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/055-008l_S2k_HIV-Praeexpositionsprophylaxe_2019-01_01.pdf"},{"key":"564_CR8","volume-title":"EACS Guidelines Version 9.1","author":"European AIDS Clinical Society","year":"2018","unstructured":"European AIDS Clinical Society (2018) EACS Guidelines Version 9.1. \n                    http:\/\/www.eacsociety.org\/files\/guidelines_9.0-german.pdf"},{"key":"564_CR9","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","volume":"390","author":"J Gallant","year":"2017","unstructured":"Gallant J, Lazzarin A, Mills A et al (2017) Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380\u20131489): a\u00a0double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet 390:2063\u20132072","journal-title":"Lancet"},{"key":"564_CR10","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1056\/NEJMct1215532","volume":"371","author":"M Gandhi","year":"2014","unstructured":"Gandhi M, Gandhi RT (2014) Single-pill combination regimens for treatment of HIV-1 infection. N\u00a0Engl J Med 371:248\u2013259","journal-title":"N Engl J Med"},{"key":"564_CR11","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","volume":"14","author":"RM Grant","year":"2014","unstructured":"Grant RM, Anderson PL, Mcmahan V et al (2014) Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a\u00a0cohort study. Lancet Infect Dis 14:820\u2013829","journal-title":"Lancet Infect Dis"},{"key":"564_CR12","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant RM, Lama JR, Anderson PL et\u00a0al (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N\u00a0Engl J Med 363:2587\u20132599","journal-title":"N Engl J Med"},{"key":"564_CR13","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1506816","volume":"373","author":"JD Lundgren","year":"2015","unstructured":"Group ISS, Lundgren JD, Babiker AG et\u00a0al (2015) Initiation of antiretroviral therapy in early asymptomatic HIV infection. N\u00a0Engl J Med 373:795\u2013807","journal-title":"N Engl J Med"},{"issue":"2","key":"564_CR14","doi-asserted-by":"publisher","first-page":"pii:30436","DOI":"10.2807\/1560-7917.ES.2017.22.2.30436","volume":"22","author":"A Hauser","year":"2017","unstructured":"Hauser A, Hofmann A, Hanke K et\u00a0al (2017) National molecular surveillance of recently acquired HIV infections in Germany, 2013 to 2014. Euro Surveill 22(2):pii:30436. \n                    https:\/\/doi.org\/10.2807\/1560-7917.ES.2017.22.2.30436","journal-title":"Euro Surveill"},{"key":"564_CR15","unstructured":"http:\/\/www.unaids.org\/en\/resources\/909090\n                    \n                  . Zugegriffen: 10. Jan. 2019"},{"key":"564_CR16","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1056\/NEJMra022812","volume":"348","author":"JM Kilby","year":"2003","unstructured":"Kilby JM, Eron JJ (2003) Novel therapies based on mechanisms of HIV-1 cell entry. N\u00a0Engl J Med 348:2228\u20132238","journal-title":"N Engl J Med"},{"key":"564_CR17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","volume":"391","author":"JM Llibre","year":"2018","unstructured":"Llibre JM, Hung CC, Brinson C et al (2018) Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet 391:839\u2013849","journal-title":"Lancet"},{"key":"564_CR18","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","volume":"390","author":"DA Margolis","year":"2017","unstructured":"Margolis DA, Gonzalez-Garcia J, Stellbrink HJ et al (2017) Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a\u00a0randomised, open-label, phase 2b, non-inferiority trial. Lancet 390:1499\u20131510","journal-title":"Lancet"},{"key":"564_CR19","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1016\/S2352-3018(17)30068-1","volume":"4","author":"M Markowitz","year":"2017","unstructured":"Markowitz M, Frank I, Grant RM et al (2017) Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a\u00a0multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV 4:e331\u2013e340","journal-title":"Lancet HIV"},{"key":"564_CR20","doi-asserted-by":"publisher","first-page":"e402","DOI":"10.1016\/S2352-3018(17)30089-9","volume":"4","author":"JM Molina","year":"2017","unstructured":"Molina JM, Charreau I, Spire B et al (2017) Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV 4:e402\u2013e410","journal-title":"Lancet HIV"},{"key":"564_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy540","author":"C Orkin","year":"2018","unstructured":"Orkin C, Squires KE, Molina JM et al (2018) Doravirine\/Lamivudine\/Tenofovir Disoproxil Fumarate is non-inferior to Efavirenz\/Emtricitabine\/Tenofovir Disoproxil Fumarate in treatment-naive adults with human Immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial. Clin Infect Dis. \n                    https:\/\/doi.org\/10.1093\/cid\/ciy540","journal-title":"Clin Infect Dis"},{"key":"564_CR22","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1016\/S0140-6736(14)61170-3","volume":"384","author":"F Raffi","year":"2014","unstructured":"Raffi F, Babiker AG, Richert L et al (2014) Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001\/ANRS143 randomised non-inferiority trial. Lancet 384:1942\u20131951","journal-title":"Lancet"},{"key":"564_CR23","volume-title":"Epidemiologisches Bulletin 47\/2018: Sch\u00e4tzung der Zahl der HIV-Neuinfektionen und der Gesamtzahl von Menschen mit HIV in Deutschland","author":"Robert Koch Institut","year":"2018","unstructured":"Robert Koch Institut (2018) Epidemiologisches Bulletin 47\/2018: Sch\u00e4tzung der Zahl der HIV-Neuinfektionen und der Gesamtzahl von Menschen mit HIV in Deutschland. \n                    https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2018\/Ausgaben\/47_18.pdf?__blob=publicationFile"},{"key":"564_CR24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jama.2018.8431","volume":"320","author":"MS Saag","year":"2018","unstructured":"Saag MS, Benson CA, Gandhi RT et al (2018) Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international Antiviral society-USA panel. JAMA 320:379\u2013396","journal-title":"JAMA"},{"key":"564_CR25","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","volume":"369","author":"SL Walmsley","year":"2013","unstructured":"Walmsley SL, Antela A, Clumeck N et al (2013) Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N\u00a0Engl J Med 369:1807\u20131818","journal-title":"N Engl J Med"},{"key":"564_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/infdis\/jiv012","volume":"212","author":"WL Yang","year":"2015","unstructured":"Yang WL, Kouyos R, Scherrer AU et\u00a0al (2015) Assessing the paradox between transmitted and acquired HIV type 1 drug resistance mutations in the Swiss HIV cohort study from 1998 to 2012. J\u00a0Infect Dis 212:28\u201338","journal-title":"J Infect Dis"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-0564-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-019-0564-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-0564-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T16:16:50Z","timestamp":1582042610000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-019-0564-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,18]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["564"],"URL":"https:\/\/doi.org\/10.1007\/s00108-019-0564-0","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,18]]},"assertion":[{"value":"18 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Lehmann hat im Rahmen von Beratungs-und Vortragst\u00e4tigkeiten Honorare von Gilead, ViiV Healthcare, Janssen-Cilag und Merck Sharp & Dohme erhalten. J.\u00a0Malin hat Reisekostenerstattungen von Gilead erhalten. I.\u00a0Su\u00e1rez hat Honorare f\u00fcr Vortragst\u00e4tigkeiten (Merck Sharp & Dohme) und Beratungst\u00e4tigkeiten (ViiV Healthcare) sowie Reisekostenerstattungen (Gilead, Janssen-Cilag, Merck Sharp & Dohme) erhalten. G.\u00a0F\u00e4tkenheuer hat Honorare f\u00fcr Vortragst\u00e4tigkeiten (Bristol-Myers Squibb, Janssen-Cilag, Merck Sharp & Dohme) und Beratungst\u00e4tigkeiten (Janssen-Cilag, Merck Sharp & Dohme) sowie Reisekostenerstattungen (Gilead, Janssen-Cilag) erhalten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}